Assay Development and Screening

New Functional Genomics toolsets: Arrayed loss of function screening with LentiArray CRISPR libraries

Wednesday, February 7
2:00 PM - 2:30 PM
Location: 6C

Identifying and validating targets that underlie disease mechanisms and can be addressed to provide efficacious therapies remains a significant challenge in the drug discovery and development process.  Mechanisms of RNAi have provided the use of siRNA and shRNA to knock-down RNA and suppress gene function.  However, depending on the nature of the targets, cells, biology and end-point assays, these approaches may suffer variously from their transient nature, design complexity, incomplete knock-down or off-target effects.  The use of CRISPR (clustered regularly interspaced short palindromic repeat)-associated Cas9 nuclease and guide RNA (gRNA) provides a strong alternative that can produce transient or long-lasting impact, straightforward design, knock-out of genes and increased specificity.  A number of laboratories have already published reports demonstrating how pools of gRNA can be delivered to cells and “hits” can be established through enrichment or depletion of cells following a “survival” assay and identified by sequencing the introduced gRNAs in the remaining cell population.  Here we demonstrate a knock-out screening approach that utilizes the Invitrogen™ LentiArray™ CRISPR library to interrogate the impact of individual gene knock-outs on the NFκB pathway as measured by a functional cell-based assay.  We describe the library design concepts, the assay development, initial screening results and validation of specific identified hits. We elucidate the key factors in developing a robust assay including both transduction and assay optimization to achieve the highest levels of transduction efficiency and assay window and provide data from initial screens using the Invitrogen™ LentiArray™ CRISPR kinome library.  We expect these approaches to be scalable to the entire human genome and portable to multiple cell types and end-point assays including both high-throughput plate-based assays and high-content imaging based assays.

Jon Chesnut

Sr. Director, R&D
Thermo Fisher Scientific

Cell and Molecular Biology, Genome Editing.

Presentation(s):

Send Email for Jon Chesnut


Assets

New Functional Genomics toolsets: Arrayed loss of function screening with LentiArray CRISPR libraries



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for New Functional Genomics toolsets: Arrayed loss of function screening with LentiArray CRISPR libraries